The Synthetic Ep 4 Beta By Carbon | Work

The second phase of carbon work involves attaching the ω-side chain (C13-C20). Researchers employ a Negishi cross-coupling between a zincated vinyl iodide and a cyclopentyl triflate. This is a textbook example of why "by carbon work" is emphasized—direct C(sp²)-C(sp³) coupling avoids protecting group gymnastics common in older syntheses.

The yield at this stage consistently exceeds 85%, even on a decagram scale, making this method industrially relevant. the synthetic ep 4 beta by carbon work

The peptide chain is typically synthesized via standard Solid Phase Peptide Synthesis (SPPS) or solution-phase coupling using protected amino acids (e.g., Boc or Fmoc chemistry). The second phase of carbon work involves attaching

Prostaglandin E2 (PGE2) is a major cyclooxygenase metabolite of arachidonic acid, exerting diverse physiological effects via four distinct G-protein coupled receptors: EP1, EP2, EP3, and EP4. Among these, the EP4 receptor has garnered significant pharmaceutical interest due to its role in stimulating bone formation and repair, as well as its gastroprotective properties. Unlike non-steroidal anti-inflammatory drugs (NSAIDs), which block prostaglandin synthesis and can inhibit bone healing, selective EP4 agonists have shown the potential to accelerate fracture repair without the systemic toxicity associated with PGE2. The yield at this stage consistently exceeds 85%,

However, the clinical translation of early EP4 agonists has been hindered by chemical instability, particularly the rapid enzymatic oxidation of the 15-hydroxyl group by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). To overcome this, the design of "synthetic EP4" analogues often focuses on modifying the upper $\omega$-chain and stabilizing the lower $\alpha$-chain via carbocyclic or heteroatom substitutions.

In this work, we present the synthesis of Compound 4β (hereafter referred to as 4β), a synthetic carbocyclic analogue designed to resist metabolic degradation while retaining high EP4 binding affinity. The synthesis focuses on the stereocontrolled installation of the 15(S)-hydroxyl group—a critical pharmacophore for receptor activation—and the replacement of the labile carboxylic acid with a stable heterocyclic bioisostere.

Early adopters of the synthetic EP 4 beta by carbon work are focusing on three high-value sectors: